Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia

Haematologica. 2018 Nov;103(11):e514-e518. doi: 10.3324/haematol.2018.191361. Epub 2018 May 24.

¹ University of Texas MD Anderson Cancer Center, Houston, TX, USA [email protected].
² Weill Cornell Medical Center, New York, NY, USA.
³ Indiana University Simon Cancer Center, Indianapolis, IN, USA.
⁴ Moffitt Cancer Center, Tampa, FL, USA.
⁵ West Virginia University, Morgantown, WV, USA.
⁶ Institut Paoli-Calmettes and Aix-Marseille University, Marseille, France.
⁷ Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
⁸ David Geffen School of Medicine at University of California, Los Angeles, CA, USA.
⁹ University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁰ Université de Bordeaux, Centre Hospitalier Universitaire de Bordeaux, France.
¹¹ University Hospital Schleswig-Holstein, Kiel, Germany.
¹² Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse III, Centre Hospitalier Universitaire de Toulouse, France.
¹³ Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
¹⁴ IRCCS AOU San Martino-IST, Genova, Italy.
¹⁵ Kaposi Mor Teaching Hospital, Kaposvar, Hungary.
¹⁶ Universitätsklinikum Münster, Germany.
¹⁷ Sunesis Pharmaceuticals, Inc., South San Francisco, CA, USA.
¹⁸ Medical University of South Carolina, Charleston, SC, USA.

No abstract available

Publication types